Goldman Sachs analyst Chris Shibutani upgrades $BioNTech (BNTX.US)$ to a buy rating, and adjusts the target price from $90 to $137.
According to TipRanks data, the analyst has a success rate of 44.4% and a total average return of 11.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $BioNTech (BNTX.US)$'s main analysts recently are as follows:
The upgrade of BioNTech's rating reflects the incorporation of projections for BNT327, an innovative immuno-oncology candidate under clinical trials for various solid tumor types, into valuation models. The investment rationale for BioNTech is observed to be shifting from the challenging-to-predict COVID-19 vaccine market to the emerging substantial opportunity presented by BNT327. Success in the development of BNT327 could significantly contribute to BioNTech's ambition of establishing a dominant commercial presence in the oncology sector.
The firm noted that while financial results surpassed expectations and forecasts were maintained, attention is now shifting to the Oncology pipeline. This area is anticipated to provide multiple data outcomes from mid-to-late stage research in the latter part of 2024 and throughout 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
高盛集團分析師Chris Shibutani上調$BioNTech (BNTX.US)$至買入評級，並將目標價從90美元上調至137美元。
根據TipRanks數據顯示，該分析師近一年總勝率為44.4%，總平均回報率為11.9%。
此外，綜合報道，$BioNTech (BNTX.US)$近期主要分析師觀點如下：
BioNTech評級的上調反映了對估值模型中，BNT327（一種正在進行各種實體瘤類型臨床試驗的創新免疫腫瘤學候選藥物）的預測已納入估值模型。據觀察，BioNTech 的投資理由正在從難以預測的 COVID-19 疫苗市場轉向 BNT327 帶來的新興實質性機遇。BNT327 的成功開發可以顯著促進 BioNTech 在腫瘤學領域建立主導商業地位的雄心。
該公司指出，儘管財務業績超出預期且預測得以維持，但現在注意力正在轉移到腫瘤學產品線上。預計該領域將在2024年下半年和整個2025年提供中後期研究的多種數據成果。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
